Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M105,105Revenue (TTM) $M37,719Net Margin (%)12.3Altman Z-Score2.0
Enterprise Value $M115,100EPS (TTM) $1.8Operating Margin %14.6Piotroski F-Score7
P/E(ttm)23.9Beneish M-Score-2.7Pre-tax Margin (%)13.5Higher ROA y-yN
Price/Book1.810-y EBITDA Growth Rate %-0.1Quick Ratio1.0Cash flow > EarningsY
Price/Sales2.95-y EBITDA Growth Rate %-4.4Current Ratio1.5Lower Leverage y-yY
Price/Free Cash Flow18.4y-y EBITDA Growth Rate %-3.8ROA % (ttm)4.2Higher Current Ratio y-yN
Dividend Yield %4.1PEG--ROE % (ttm)7.5Less Shares Outstanding y-yY
Payout Ratio %92.0Shares Outstanding M2,574ROIC % (ttm)6.7Gross Margin Increase y-yY

Gurus Latest Trades with SNY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYKen Fisher 2016-12-31 Add$37.06 - $42.01
($39.4)
$ 40.964%Add 0.39%12,492,035
SNYBill Nygren 2016-09-30 Reduce-0.67%$37.83 - $42.63
($40.13)
$ 40.962%Reduce -42.05%3,170,000
SNYBarrow, Hanley, Mewhinney & Strauss 2016-09-30 Add0.19%$37.83 - $42.63
($40.13)
$ 40.962%Add 11.37%31,320,327
SNYNWQ Managers 2016-09-30 Buy 0.19%$37.83 - $42.63
($40.13)
$ 40.962%New holding335,521
SNYDodge & Cox 2016-09-30 Add0.15%$37.83 - $42.63
($40.13)
$ 40.962%Add 7.45%59,267,298
SNYHOTCHKIS & WILEY 2016-09-30 Add0.1%$37.83 - $42.63
($40.13)
$ 40.962%Add 5.33%12,041,028
SNYKen Fisher 2016-09-30 Reduce-0.1%$37.83 - $42.63
($40.13)
$ 40.962%Reduce -8.76%12,443,197
SNYCharles Brandes 2016-09-30 Reduce-0.03%$37.83 - $42.63
($40.13)
$ 40.962%Reduce -1.19%3,557,856
SNYJohn Paulson 2016-09-30 Add0.01%$37.83 - $42.63
($40.13)
$ 40.962%Add 5.44%417,000
SNYJoel Greenblatt 2016-09-30 Reduce$37.83 - $42.63
($40.13)
$ 40.962%Reduce -7.57%32,879
SNYNWQ Managers 2016-06-30 Sold Out -1.22%$38.13 - $44.32
($40.99)
$ 40.96-0%Sold Out0
SNYDavid Dreman 2016-06-30 Add0.47%$38.13 - $44.32
($40.99)
$ 40.96-0%Add 980.43%20,204
SNYHOTCHKIS & WILEY 2016-06-30 Add0.23%$38.13 - $44.32
($40.99)
$ 40.96-0%Add 12.47%11,432,112
SNYJohn Paulson 2016-06-30 Buy 0.17%$38.13 - $44.32
($40.99)
$ 40.96-0%New holding395,500
SNYDodge & Cox 2016-06-30 Add0.07%$38.13 - $44.32
($40.99)
$ 40.96-0%Add 3.04%55,155,913
SNYBarrow, Hanley, Mewhinney & Strauss 2016-06-30 Reduce-0.06%$38.13 - $44.32
($40.99)
$ 40.96-0%Reduce -3.32%28,122,279
SNYCharles Brandes 2016-06-30 Add0.03%$38.13 - $44.32
($40.99)
$ 40.96-0%Add 1.24%3,600,731
SNYKen Fisher 2016-06-30 Add0.01%$38.13 - $44.32
($40.99)
$ 40.96-0%Add 0.67%13,638,183
SNYJoel Greenblatt 2016-06-30 Add$38.13 - $44.32
($40.99)
$ 40.96-0%Add 2.45%35,571
SNYCharles Brandes 2016-03-31 Add0.78%$38.37 - $42.65
($40.17)
$ 40.962%Add 61.76%3,556,721
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-56.88view
Sanofi10% Owner 2015-01-26Buy647,448$95-56.88view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-56.04view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-38.76view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67434.03view

Press Releases about SNY :

Quarterly/Annual Reports about SNY:

    News about SNY:

    Articles On GuruFocus.com
    David Herro's Oakmark International Fund Fourth Quarter Letter Jan 11 2017 
    Something Strange Is Going On With Oral Insulin Dec 23 2016 
    Dodge & Cox Invests in 7 Positions in the 3rd Quarter Dec 19 2016 
    Warren Buffett’s Only Dividend Stocks With 4%-Plus Yields Nov 29 2016 
    World Leader in Diabetes Medication Hits 2-Year Low Nov 07 2016 
    First Eagle Investments Comments on Sanofi Oct 24 2016 
    Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
    Novo Nordisk Is Being Ignored Oct 06 2016 
    Take a Look at Sanofi Oct 05 2016 
    John Paulson Trims Synergy Sep 23 2016 

    More From Other Websites
    Regeneron, Sanofi Claim Amgen's LDL-Buster Patent Too Broad Jan 17 2017
    Sanofi: SuliquaTM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes Jan 17 2017
    1:22 pm Sanofi announces that the European Commission has granted marketing authorization in Europe... Jan 17 2017
    Key FDA Events to Watch Out for in Q1 Jan 17 2017
    5 Trump-Proof Pharma Dividends Up To 5.3% Jan 16 2017
    Odds Are Against Regeneron, Sanofi In Amgen Patent Battle: Leerink Jan 13 2017
    Sanofi, ImmuNext Sign $500M Autoimmune Drug Pact Jan 13 2017
    Insulin Drug Offers Hope for MannKind Jan 12 2017
    Regeneron, Sanofi's Drug Manufacturing Plant Cleared Jan 12 2017
    Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases Jan 10 2017
    The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron... Jan 10 2017
    Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit Jan 10 2017
    Sanofi Sees No Opening to Actelion Talks After J&J Re-Entry Jan 09 2017
    Morgan Stanley Cuts Regeneron Target On Praluent Patent Worries Jan 09 2017
    Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit Jan 09 2017
    Sanofi and ImmuNext Enter into Agreement to Develop Treatments for Autoimmune Diseases Jan 09 2017
    [$$] Regeneron Is Down, Not Out Jan 08 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)